18 Aug 2008: AHFS Drug Information August 2008 update
AHFS Drug Information updated with 19 revised and 2 new monographs
This update contains 19 revised and 2 new monographs. For full details,
click here (PDF).
08 Jul 2008: AHFS Drug Information July 2008 update
AHFS Drug Information updated with 17 revised monographs
This update contains 17 revised monographs. For full details, click here (PDF).
18 Jun 2008: AHFS Drug Information June 2008 update
AHFS Drug Information updated with 7 revised monographs and 1 new monograph
This update contains 7 revised monographs and 1 new monograph. A MedWatch notice was added to varenicline, aprotinin, and mycophenolate.
Full
details (PDF).
08 May 2008: AHFS Drug Information May 2008 update
AHFS Drug Information updated with 10 revised monographs
This update contains 10 revised monographs. The monographs for maraviroc and etravirine were expanded from firstReleases to an Overviews and a MedWatch notice was added to etanercept.
Full
details (PDF).
22 Apr 2008: AHFS Drug Information April 2008 update
AHFS Drug Information updated with 15 revised monographs and 1 new monograph
This update contains 15 revised monographs and one new monograph. Two monographs were revised due to FDA MedWatch notices. The monograph for raltegravir was expanded from a firstRelease to an Overview.
Full
details (PDF).
20 Mar 2008: First 2008 update
AHFS Drug Information update corresponds to the 2008 print edition
This update, corresponding to the 2008 print edition, has been updated extensively, and includes MedWatch notices that were issued in January/February 2008.
Full
details (PDF).
19 Dec 2007: AHFS Drug Information December 2007 update
AHFS Drug Information updated with 61 revised monographs
This update contains 61 revised monographs. The monographs for telbivudine, lapatinib, and paliperidone were expanded from firstReleases to Overviews.
Full
details (PDF).
06 Nov 2007: AHFS Drug Information November 2007 update
AHFS Drug Information updated with 64 revised and 2 new monographs
This update contains 64 revised monographs. It also contains 2 new monographs: maraviroc and raltegravir.
Full
details (PDF).
17 Oct 2007: AHFS Drug Information October 2007 update
AHFS Drug Information updated with 21 revised and 3 new monographs
This update contains 3 new monographs and 21 revisions. Posaconazole was upgraded from a FirstRelease monograph to an Overview monograph. The new monographs are:
- Temsirolimus
- Levocetirizine
- Eculizumab
The revised monographs are:
- Risedronate
- Zoledronic Acid
- Clopidogrel
- Pergolide
- Ibritumomab
- Budesonide
- Ibandronate
- Posaconazole
- Azathioprine
- Haloperidol
- Trimipramine
- Desipramine
- Imipramine
- Fentanyl
- Pyrethrins with Piperonyl Butoxide (Topical)
- Etidronate
- Ceftriaxone
- Terconazole (Topical)
- Pamidronate
- Valacyclovir
- Alendronate
13 Sep 2007: AHFS Drug Information September 2007 update
AHFS Drug Information updated with 19 revised and 5 new monographs
This update contains 5 new monographs and 19 revisions. Anidulafungin was upgraded from a FirstRelease monograph to an Overview monograph.
09 Aug 2007: AHFS Drug Information August 2007 update
AHFS Drug Information updated with 8 revised and 2 new monographs
This update contains 8 revised monographs. It also contains 2 new monographs: aliskirin hemifumarate and lisdexamfetamine dimesylate. Aliskirin has been preliminarily assigned to class 24:32. However, a new sub-classification 24:32.40 - "Renin Inhibitors" - will be created, and this drug will be moved to the new class in due course.
19 Jul 2007: AHFS Drug Information July 2007 update
AHFS Drug Information updated with 17 revised and 1 upgraded monograph
This update contains 17 revised monographs. It also includes 1 monograph (sorafenib) that was upgraded from a firstRelease to an Overview.
06 Jun 2007: AHFS Drug Information June 2007 update
AHFS Drug Information updated with 6 revised and 1 upgraded monograph
This update contains 6 revised monographs (pegaptanib (EENT), metronidazole, minoxidil, rimantadine, zanamivir, oseltamivir) and 1 monograph (ranolazine) that was upgraded from a firstRelease to an Overview.
14 May 2007: AHFS Drug Information May 2007 update
AHFS Drug Information updated with 9 revised monographs
This update contains 9 revised monographs: docosanol (topical), tizanidine, telithromycin, rotavirus vaccine live oral, acetaminophen, estrogen-progestin combinations, trimethobenzamide, norfloxacin, ofloxacin.
Of these, 3 monographs were revised due to Medwatch notices from the FDA (telithromycin, tizanidine, trimethobenzamide, and rotavirus vaccine).
19 Apr 2007: AHFS Drug Information April 2007 update
AHFS Drug Information updated with 2 new monographs and 39 revised monographs
This update contains 2 new monographs and 39 revised monographs. A total of 21 monographs were revised due to Medwatch notices from the FDA (atomoxetine, cyclosporine, darbepoetin, dexmethylphenidate, dextroamphetamine, entecavir, epoetin alfa, eszopiclone, interferon gamma, linezolid, methylphenidate, mycophenolate, omalizumab, pioglitazone, ramelteon, rosiglitazone, tacrolimus, temazepam, triazolam, zaleplon, zolpidem). In addition, the new monograph, Sitagliptin, has been added to a new therapeutic class: "68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors".
09 Mar 2007: First 2007 update
AHFS Drug Information updated with 28 new monographs
This update, corresponding to the 2007 print edition, has been updated extensively, incorporating revised information on uses, therapeutic perspectives, cautions, drug interactions, new products, and other new developments. Each year more than 60% of the monographs are revised. The coverage in the 2007 edition has been expanded by 28 new drug monographs.
18 Dec 2006: AHFS Drug Information December 2006 update
AHFS Drug Information updated with 71 revised and 4 new monographs
This update contains 71 revised monographs and 4 new monographs (posaconazole, dasatinib, rasagiline, ranibizumab). Oseltamivir was revised due to an FDA MedWatch notice. Other revisions of note were made due to updated guidelines and treatment recommendations from the National Lipid Association (HMG CoA Redutase Inhibitors) and the American Heart Association CPR guidelines (mexiletine, flecainide, ibutilide, and propafenone).
28 Nov 2006: AHFS Drug Information November 2006 update
AHFS Drug Information updated with 40 revised monographs
This update contains 40 revised monographs. Two monographs (decitabine and varenicline) were enhanced from a firstRelease to an overview format (additional precautionary information and drug interactions). Five monographs were revised due to FDA MedWatch notices (imatinib, lamotrigine, meningococcal vaccine, warfarin, and venlafaxine).
18 Oct 2006: AHFS Drug Information October 2006 update
AHFS Drug Information updated with 19 monographs
This update contains 19 monographs, consisting of 1 new monograph, and 18 revised monographs. Of these, 5 monographs were revised due to MedWatch notices (aspirin, bevacizumab, estrogens, ibuprofen, and salicylates general statement).
26 Sep 2006: AHFS Drug Information September 2006 update
AHFS Drug Information updated with 4 new and 34 revised monographs
This update contains 38 monographs, consisting of 4 new monographs (insulin detemir, anidulafungin, decitabine, varenicline), and 34 revised monographs. Three monographs were expanded from AHFS firstReleases to AHFS Overviews (nelarabine, pramlintide, nepafenac). Three monographs were revised due to a MedWatch notice from the FDA regarding amphetamine use and sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. 12 monographs were revised with new product listings, and the Estrogen-Progestin Combination monograph was revised to include information on the recently approved "Plan B" for postcoital contraception.
11 Sep 2006: AHFS Drug Information August 2006 update
AHFS Drug Information updated with 31 revised monographs
This update contains 3 new monographs and 31 revised monographs. Of these, 16 monographs were revised due to MedWatch alerts. Most of these alerts related to a new warning from the FDA regarding the occurrence of serotonin syndrome in individuals taking medications commonly used to treat migraine headaches with certain types of antidepressants and mood disorder medications.
18 Jul 2006: AHFS Drug Information July 2006 update
AHFS Drug Information updated with 10 revised monographs
The New England Journal of Medicine recently published an article reporting that infants whose mothers had taken an angiotensin-converting enzyme inhibitor (ACE inhibitors) drug during the first trimester of pregnancy had an increased risk of major congenital malformations, compared with infants who had not undergone first trimester exposure to ACE inhibitor drugs. The FDA-approved labels recommends discontinuing the ACEI as soon as possible if a patient becomes pregnant. ACE inhibitor drugs are labeled pregnancy category C for the first trimester of pregnancy, and are labeled pregnancy category D during the second and third trimesters. Healthcare professionals should take these findings into consideration with other information about a patient's medical situation when prescribing ACE inhibitors. At this time, based on this one observational study, the FDA does not plan to change the pregnancy categories for ACE inhibitors. FDA will work with the Agency for Healthcare Quality and Research to identify other potential sources of data that will help determine the degree of risk associated with first trimester exposures to these drugs. This prompted revisions to the 10 ACEI monographs in AHFS Drug Information.
12 Jun 2006: AHFS Drug Information June 2006 update
AHFS Drug Information updated with new and revised monographs and new precautionary information
Seven new monographs have been added to the database, reflecting recent new drug approvals by the FDA:
- Omega-3-acid Ethyl Esters, approved as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with TG levels >/= 500 mg/dL
- Abatacept, approved for reducing the signs and symptoms of rheumatoid arthritis (RA), inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists
- Mecasermin, approved for long-term treatment of a rare type of hormone deficiency that causes children to be much shorter than their peers and to grow at a much slower rate; a human insulin-like growth factor-1 (IGF-1) produced by recombinant DNA technology
- Lenalidomide, approved for myelodysplastic syndrome (but a supplemental new drug application (sNDA) has already been filed for relapsed or refractory multiple myeloma)
- Sorafenib, approved for advanced renal cell carcinoma (RCC)
- Lubiprostone, approved for chronic idiopathic constipation
- Insulin Glulisine, a human insulin analog that is a rapid-acting, parenteral blood glucose lowering agent
The following monographs have been updated to include new precautionary information issued by the FDA (MedWatch Notices): Gatifloxacin, Telithromycin, Aprotinin, Nimodipine, Clozapine, Benzocaine, Pimecrolimus, Denileukin, Bosentan, Mifepristone, Paroxetine, Rosiglitazone, and Immune Globulin.
In addition, 156 other monographs have been revised, including updated product listings.
08 May 2006: First release on MedicinesComplete
AHFS Drug Information provides up-to-date information on tens of thousands of drug products
The coverage of the 2006 edition has been expanded to include 31 new drug monographs:
- Increased granularity of the AHFS Classification and CMS Medicare Part D recognition
- Extensively revised product listings
- Current authoritative therapeutic guidelines updated
- Major cautionary information revised
08 May 2006: Now Available - AHFS
American Hospital Formulary Service Now Available
The American Hospital Formulary Service (AHFS)is now available on MedicinesComplete.
For further information, please see (PDF).
Users wishing to subscribe to AHFS may do so by contacting their regional sales team as detailed below:
UK & ROW
Pharmaceutical Press
1 Lambeth High Street
London
SE1 7JN
Tel: +44 (0)20 7572 2464
Email: sales@medicinescomplete.com
The Americas
Pharmaceutical Press
1537 St. Paul Avenue
Gurnee Illinois 60031
Tel: +1 877 471 4747
Email: sales_americas@pharmpress.com
Or select 'Subscribe' on the MedicinesComplete homepage
